Our Science – Annunziata Website
Christina M. Annunziata, M.D., Ph.D.
Selected Publications |
 |
| 1)
Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer. 119: 1357-64, 2013. [Journal] |
|
| 2)
Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am. J. Hematol. 88: 89-92, 2013. [Journal] |
|
| 3)
Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Mol. Cell Proteomics. [Epub ahead of print], 2013. [Journal] |
|
| 4)
Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer. 118: 1543-53, 2012. [Journal] |
|
| 5)
Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc. Natl. Acad. Sci. U.S.A. 109: E3659-67, 2012. [Journal] |
|
| 6)
Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM. IKK-e coordinates invasion and metastasis of ovarian cancer. Cancer Res. 72: 5494-504, 2012. [Journal] |
|
| 7)
Annunziata CM, Kohn EC, Lorusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. [Epub ahead of print], 2012. [Journal] |
|
| 8)
Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood. 117: 2396-404, 2011. [Journal] |
|
| 9)
Driscoll JJ, Burris J, Annunziata CM. Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy. Am J Ther. 19: 133-44, 2011. [Journal] |
|
| 10)
Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 70: 4005-14, 2010. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/5/2013.
